Compare NSIT & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSIT | BHC |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 1995 | N/A |
| Metric | NSIT | BHC |
|---|---|---|
| Price | $85.84 | $7.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $128.33 | $8.67 |
| AVG Volume (30 Days) | 437.3K | ★ 2.9M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.21 | 0.97 |
| Revenue | $8,271,548,000.00 | ★ $10,029,000,000.00 |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | $2.57 | $4.11 |
| P/E Ratio | $20.30 | ★ $7.25 |
| Revenue Growth | N/A | ★ 5.86 |
| 52 Week Low | $81.59 | $4.25 |
| 52 Week High | $181.92 | $8.69 |
| Indicator | NSIT | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 56.91 |
| Support Level | $83.33 | $6.66 |
| Resistance Level | $87.07 | $7.20 |
| Average True Range (ATR) | 2.31 | 0.30 |
| MACD | 0.75 | 0.04 |
| Stochastic Oscillator | 40.87 | 63.92 |
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.